Amgen Beats $50 Million Blincyto Verdict in Lindis Case (1)

Amgen Inc. persuaded a federal judge to throw out a $50.3 million verdict after he found Lindis Biotech GmbH withheld key information from the US Patent and Trademark Office when seeking two patents for antibody treatment methods that jurors found Amgen’s leukemia drug Blincyto infringes.

Lindis committed inequitable conduct before the PTO, rendering US Patent Nos. 10,071,158 and 8,709,421 unenforceable, Judge Gregory B. Williams ruled in an order issued Thursday in the US District Court for the District of Delaware.

The ruling, issued alongside a sealed opinion, nullifies a December jury verdict that awarded Lindis a 2.25% royalty on $2.2 ...